Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
90 hedge funds and large institutions have $121M invested in Bellicum Pharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 26 reducing their positions, and 18 closing their positions.
19% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 26
6% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 18
1% less funds holding
Funds holding: 91 → 90 (-1)
21% less capital invested
Capital invested by funds: $154M → $121M (-$32.6M)
53% less call options, than puts
Call options by funds: $596K | Put options by funds: $1.26M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$3.96M |
| 2 |
AC
Ascend Capital
Orinda,
California
|
+$3.03M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$2.64M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$1.09M |
| 5 |
Millennium Management
New York
|
+$918K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$6.65M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.79M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$1.47M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.31M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.05M |
BLCM Hedge Fund Activity: Q1 2018 in Review
90 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q1 2018, worth a combined $121M — down 21% from $154M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new BLCM positions and 18 closed out — a net gain of 1 holder — while 31 added to existing stakes and 26 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $3.96M. The largest seller was Baker Bros. Advisors, cutting an estimated $6.65M.
- 90 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q1 2018, down from 91 in Q4 2017.
- Funds reported $121M of Bellicum Pharmaceuticals, Inc. stock for Q1 2018, down 21% quarter-over-quarter.
- 19 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q1 2018 and 18 closed out, a net change of +1 holder.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q1 2018 was JP Morgan Chase, an estimated $3.96M added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q1 2018 was Baker Bros. Advisors, an estimated $6.65M sold.
Based on aggregated 13F filings for Q1 2018.